FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Peptide Therapy Showdown: Tirzepatide vs. Semaglutide in Obesity and Metabolic Syndrome
研究ライブラリに戻る

Peptide Therapy Showdown: Tirzepatide vs. Semaglutide in Obesity and Metabolic Syndrome

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Peptide Therapy Showdown: Tirzepatide vs. Semaglutide in Obesity and Metabolic Syndrome

A new clinical trial comparing two popular GLP-1 receptor agonists, tirzepatide and semaglutide, has begun enrolling participants to determine which peptide therapy is more effective for treating obesity and metabolic syndrome.

Background

The ongoing battle against obesity and its associated metabolic complications like type 2 diabetes and cardiovascular disease has seen significant advancements in recent years. Among the most promising treatments are GLP-1 receptor agonists, a class of peptides that mimic incretin hormones to regulate blood sugar levels and promote weight loss. Two leading players in this field are tirzepatide and semaglutide, both showing remarkable results in clinical trials and gaining popularity among clinicians and researchers.

This new study, sponsored by Tri-Service General Hospital, aims to provide a head-to-head comparison of these two therapies under real-world conditions. The trial will assess not only weight loss but also broader metabolic improvements such as fat distribution changes, liver health, muscle strength, and cardiovascular markers in adults aged 20 to 65 with obesity or metabolic syndrome.

Key Details

The randomized, open-label study involves 120 participants who will be equally divided between the tirzepatide and semaglutide groups. Both groups will receive their respective peptide therapy along with lifestyle modification support, ensuring that each participant receives comprehensive care tailored to their needs.

Researchers will use advanced imaging techniques such as DXA scans to measure body composition changes over time, including regional fat distribution and bone mineral density (BMD). Additionally, MRI scans will assess liver fat content, providing a deeper understanding of how these peptides affect fatty liver disease. Other assessments include skinfold thickness measurements for precise body fat estimates, grip strength tests for muscle health evaluation, fasting blood work to monitor biochemical markers, and AI-processed ECGs to gauge cardiovascular health.

Centralized biobanking will also play a crucial role in this study by collecting serum, plasma, and peripheral blood mononuclear cells (PBMCs) from all participants. These biological samples will be stored for future targeted analyses, potentially revealing new insights into the mechanisms of action and long-term effects of these peptide therapies.

Key Takeaways

  • Head-to-Head Comparison: The study directly compares tirzepatide and semaglutide in managing obesity and metabolic syndrome.
  • Comprehensive Assessment: Participants undergo thorough evaluations at baseline, six months, and 12 months using advanced imaging and biochemical tests.
  • Lifestyle Modifications: Both peptide therapies are combined with lifestyle changes to enhance efficacy.
  • Biobanking for Future Research: Biological samples will be stored for future studies to explore long-term impacts.

What This Means

This clinical trial holds significant implications for the peptide research community, clinicians, and individuals seeking effective weight loss solutions. By providing a direct comparison of tirzepatide and semaglutide, it offers valuable insights into which therapy may offer superior benefits in terms of weight management, metabolic improvements, and overall health outcomes.

Moreover, the detailed phenotyping and biobanking strategies employed in this study set a high standard for future research on peptide therapies. These methods ensure that researchers can explore not just immediate effects but also long-term impacts on various aspects of health, paving the way for more personalized treatment approaches based on individual patient profiles.

---

Source: ClinicalTrials.gov — Published 2026-05-15

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。